You haven't searched anything yet.
Salary Range: $176,000 - $198,500
The pay range for this position is expected to be between $176,000 - $198,500/annually; however, the base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills and experience. The total compensation package for this position also includes medical benefits, 401(k) eligibility, vacation, sick time, and parental leave. Additional details of participation in these benefit plans will be provided if an employee receives an offer of employment.
If hired, employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other payment or compensation program) at any time, including reasons related to individual performance, Company or individual department/team performance, and market factors.
Scilex Holding Company’s pay range data is provided in accordance with local state pay transparency regulations. Scilex Holding Company may post different minimum wage ranges for permanent residency petitions pursuant to US Department of Labor requirements.
Scilex Holding Company is committed to equal employment opportunities, and a workplace that embraces diversity and inclusion for qualified individuals of all backgrounds.
About Scilex
SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.
The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. Click here for ZTLido’s Important Safety Information and US Prescribing Information.
We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYBTM, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. We launched ELYXYBTM in the U.S. in April 2023 and are planning to commercialize GLOPERBA in 2024.
Our three product candidates are (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXATM”), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica and has received Fast Track Status from the FDA. Currently there is no FDA approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain (“LBP”) and has received Fast Track Status from the FDA; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States.
SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most. Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.
If you’re a high-energy, compassionate, and collaborative individual with a strong desire to make a difference in patient’s lives, we encourage you to consider joining the Scilex Holding team!
Role and Responsibilities
The Regional Business Director will be responsible for successfully hiring and leading a sales launch team, promoting non-opioid pain therapies. The RBD II will establish, lead, and develop a team of high-performing sales professionals that execute against the marketing plan and sales goals. The RBD II must ensure that all activities fall within the corporate compliance guidelines and that representatives operate in a legal and ethical manner. Successful leadership, a record of hiring, coaching, developing, promoting, and retaining top talent within the span of control, and the ability to effectively manage the performance of the team. Provide clear direction and feedback of results achieved. Partner closely with the marketing teams and other sales channels to develop synergistic sales plans.
Qualifications and Education Requirements
Preferred Skills
Established competencies to include:
Action Oriented, Business Acumen, Clinical Knowledge, Drive for Results, Influence, Interpersonal Skills, Managerial Courage; Negotiation, Problem Solving, Strategic Agility; Executive Presence.
Full Time
$136k-202k (estimate)
04/28/2024
05/14/2024
scilexpharma.com
SAN DIEGO, CA
50 - 100
2019
ANTHONY P MACK
$10M - $50M
Scilex, a majority-owned subsidiary of Sorrento located in San Diego, California, responsibly develops and brings branded pharmaceutical products to market using technologies designed to maximize quality of life. We are uncompromising in our focus to become the global pharmaceutical leader committed to social, environmental, economic, and ethical principles. Dedicated to using international partnerships, we strive to deliver next generation products that are Responsible By Design.